Mahal B A, Aizer A A, Ziehr D R, Hyatt A S, Lago-Hernandez C, Chen Y-W, Choueiri T K, Hu J C, Sweeney C J, Beard C J, D'Amico A V, Martin N E, Trinh Q-D, Nguyen P L
Harvard Medical School, Boston, MA, USA.
Harvard Radiation Oncology Program, Boston, MA, USA.
Prostate Cancer Prostatic Dis. 2014 Sep;17(3):273-9. doi: 10.1038/pcan.2014.23. Epub 2014 Jul 1.
The Affordable Care Act (ACA) aims to expand health insurance coverage to over 30 million previously uninsured Americans. To help evaluate the potential impact of the ACA on prostate cancer care, we examined the associations between insurance coverage and prostate cancer outcomes among men <65 years old who are not yet eligible for Medicare.
The Surveillance, Epidemiology and End Results Program was used to identify 85 203 men aged <65 years diagnosed with prostate cancer from 2007 to 2010. Multivariable logistic regression modeled the association between insurance status and stage at presentation. Among men with high-risk disease, the associations between insurance status and receipt of definitive therapy, prostate cancer-specific mortality (PCSM) and all-cause mortality were determined using multivariable logistic, Fine and Gray competing-risks and Cox regression models, respectively.
Uninsured patients were more likely to be non-white and come from regions of rural residence, lower median household income and lower education level (P<0.001 for all cases). Insured men were less likely to present with metastatic disease (adjusted odds ratio (AOR) 0.23; 95% confidence interval (CI) 0.20-0.27; P<0.001). Among men with high-risk disease, insured men were more likely to receive definitive treatment (AOR 2.29; 95% CI 1.81-2.89; P<0.001), and had decreased PCSM (adjusted hazard ratio 0.56; 95% CI 0.31-0.98; P=0.04) and all-cause mortality (adjusted hazard ratio 0.60; 0.39-0.91; P=0.01).
Insured men with prostate cancer are less likely to present with metastatic disease, more likely to be treated if they develop high-risk disease and are more likely to survive their cancer, suggesting that expanding health coverage under the ACA may significantly improve outcomes for men with prostate cancer who are not yet eligible for Medicare.
《平价医疗法案》(ACA)旨在将医疗保险覆盖范围扩大到3000多万此前未参保的美国人。为了帮助评估ACA对前列腺癌治疗的潜在影响,我们研究了65岁以下尚未符合医疗保险资格的男性的保险覆盖情况与前列腺癌治疗结果之间的关联。
利用监测、流行病学和最终结果计划,确定了2007年至2010年期间85203名年龄小于65岁且被诊断患有前列腺癌的男性。多变量逻辑回归模型分析了保险状况与确诊时疾病分期之间的关联。在患有高危疾病的男性中,分别使用多变量逻辑回归、Fine和Gray竞争风险模型以及Cox回归模型确定保险状况与接受确定性治疗、前列腺癌特异性死亡率(PCSM)和全因死亡率之间的关联。
未参保患者更有可能是非白人,来自农村地区,家庭收入中位数较低且教育水平较低(所有情况P<0.001)。参保男性出现转移性疾病的可能性较小(调整后的优势比[AOR]为0.23;95%置信区间[CI]为0.20-0.27;P<0.001)。在患有高危疾病的男性中,参保男性更有可能接受确定性治疗(AOR为2.29;95%CI为1.81-2.89;P<0.001),且PCSM降低(调整后的风险比为0.56;95%CI为0.31-0.98;P=0.04)以及全因死亡率降低(调整后的风险比为0.60;0.39-0.91;P=0.01)。
患有前列腺癌的参保男性出现转移性疾病的可能性较小,如果患上高危疾病更有可能接受治疗,且更有可能从癌症中存活下来,这表明根据ACA扩大医保覆盖范围可能会显著改善尚未符合医疗保险资格的前列腺癌男性的治疗结果。